Expert Opinion on Therapeutic Targets

The return of two old targets?
pp. 785-788(4)
Author: Suckling, Keith E

Should every lung cancer patient be tested for EGFR mutation?
pp. 789-791(3)
Author: Cappuzzo, Federico

Forthcoming receptor tyrosine kinase inhibitors
pp. 793-797(5)
Authors: Choong, Nicholas W; Cohen, Ezra EW

Cell adhesion molecules as therapeutic targets: interview with Professor Michael P Schön
pp. 799-802(4)
Author: Quigley, Emma

B lymphocytes as therapeutic targets in systemic lupus erythematosus
pp. 803-815(13)
Authors: Hasler, Paul; Zouali, Moncef

The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder
pp. 817-831(15)
Authors: Philipp, Sandra; Wolk, Kerstin; Kreutzer, Stephanie; Wallace, Elizabeth; Ludwig, Nina; Roewert, Joachim; Höflich, Conny; Volk, Hans-Dieter; Sterry, Wolfram; Sabat, Robert

Targets of emerging therapies for viral hepatitis B and C
pp. 833-850(18)
Authors: Yerly, Daniel; Di Giammarino, Loriana; Bihl, Florian; Cerny, Andreas

Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview
pp. 851-866(16)
Authors: Gazi, Irene F; Mikhailidis, Dimitri P

A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis
pp. 867-876(10)
Authors: Baka, Sofia; Clamp, Andrew R; Jayson, Gordon C

Epidermal growth factor receptor as a major anticancer drug target
pp. 877-888(12)
Authors: Caponigro, Francesco; Milano, Amalia; Ottaiano, Alessandro; Iaffaioli, Rosario Vincenzo

Aquaporins: a promising target for drug development
pp. 889-909(21)
Authors: Jeyaseelan, Kandiah; Sepramaniam, Sugunavathi; Armugam, Arunmozhiarasi; Wintour, E Marelyn

Therapeutic effects of nitric oxide-aspirin hybrid drugs
pp. 911-922(12)
Authors: Turnbull, Catriona M; Rossi, Adriano G; Megson, Ian L

Chromatin modification and muscle differentiation
pp. 923-934(12)
Authors: Yahi, Hakima; Philipot, Ophélie; Guasconi, Valentina; Fritsch, Lauriane; Ait-Si-Ali, Slimane